PetVivo Holdings Announces Release Of Clinical Study Results Involving Feline Tolerance To Intra-Articular Injections Of Spryng With OsteoCushion Technolgoy
Portfolio Pulse from Benzinga Newsdesk
PetVivo Holdings, Inc. announced the release of clinical study results conducted by Inotiv, Inc., demonstrating the safety of Spryng with OsteoCushion Technology for intra-articular injections in cats. The study showed Spryng's excellent safety profile, similar to a benign control, in managing joint-related afflictions in companion animals.
February 07, 2024 | 1:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PetVivo Holdings, Inc. announced successful clinical study results for Spryng, indicating a positive safety profile for use in cats. This development could enhance the company's reputation and market position in veterinary medical devices.
The release of positive clinical study results typically has a favorable impact on a company's stock price, especially when it involves innovative products like Spryng. This development could lead to increased investor confidence in PetVivo's product pipeline and market potential, potentially driving up PETV's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100